


TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
Army 160
HG
KA

In Re Application Of: **Sherman**



Serial No.	Filing Date	Examiner	Group Art Unit
09/544,108	April 6, 2000	Wortman, D.	1648

Title: **Composition and Method f Treating Hepatitis C**

Address to:
Assistant Commissioner for Patents
Washington, D.C. 20231

37 CFR 1.97(b)

1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p).

05/18/2002 MVILLARI 00000004 210380 09544108

01 FC:126


180.00 CH

RECEIVED
MAY 08 2002
TECH CENTER 1600/2900

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(e))

Docket No.
Army 160

In Re Application: **Sherman**



Serial No. 09/544,108	Filing Date April 6, 2000	Examiner Wortman, D.	Group Art Unit 1648
--------------------------	------------------------------	-------------------------	------------------------

Composition and Method f Treating Hepatitis C

RECEIVED
MAY 08 2002
TECH CENTER 1600/2900

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- A check in the amount of _____ is attached.
- The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 21-0380 as described below. A duplicate copy of this sheet is enclosed.
- Charge the amount of \$180.00
- Credit any overpayment.
- Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited 5-2-02 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Caroline Nash

Signature of Person Mailing Correspondence

Caroline Nash

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Caroline Nash

Signature

Caroline Nash, Reg. No. 36,329

Nash & Titus, LLC

3415 Brookeville Road

Brookeville, MD 20833

(301) 924-9500

Dated: 5-2-02

CC:

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				Docket Number (Optional) Army 16		Application Number 09/544,108	
				Applicant(s) Sherman			
				Filing Date April 6, 2000	Group Art Unit 1648		
PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A	5,849,696	12/15/98	Chretien et al.	514	12	11/4/93
	B	4,079,127	3/14/78	Goldstein et al.	424	177	2/8/77
	C	5,308,833	5/3/94	Scharschmidt et al.	514	12	2/6/92
	D	5,467,729	11/21/95	Chretien, et al.	514	2	10/26/93
FOREIGN PATENT DOCUMENTS							
REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
aa	Lok, et al., Long-Term Follow-Up in a Randomised Controlled Trial of Recombinant Alpha2-Interferon in Chinese Patients With Chronic Hepatitis B Infection, Lancet, 1988, 2: 298-302						
bb	Garcia, et al., Adenine Arabinoside Monophosphate (Vidarabine Phosphate) combination with Human Leukocyte Interferon in the Treatment of Hepatitis B, Annals of Internal Medicine, 1987: 107: 278-285.						
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Docket Number (Optional) Army 160	Application Number 09/544,108
Applicant(s) Sherman	
Filing Date April 6, 2000	Group Art Unit 1648

RECEIVED
MAY 08 2000
TECH CENTER 1600/2300

*EXAMINER INITIAL	OTHER DOCUMENTS <i>(including Author, Title, Date, Pertinent Pages, Etc.)</i>
cc	Huang, et al., Thymosin Treatment Modulates Production of Interferon, J. of Interferon Research, Vol. 1, Number 3, 1981
dd	Lok, et al., Interferon Antibodies may Negate the Antiviral Effects of Recombinant Alpha-Interferon Treatment in Patients with Chronic Hepatitis B Virus Infection, Hepatology, Vol. 12, No. 6, 1990
ee	Mutchnick, et al., Thymosin Treatment of Chronic Hepatitis B: a Placebo-Controlled Pilot Trial, Hepatology, 1991, Sep; 14(3): 409-415.
ff	Bodenheimer, et al., A Randomized, Controlled Trial of Interferon Alfa-2b Alone and After Prednisone Withdrawal For The Treatment of Chronic Hepatitis B, New England Journal of Medicine; Aug. 2, 1990, 295-301.
gg	Lok, et al., Thrice Weekly Lymphoblastoid Interferon is Effective in Inhibiting Hepatitis B Virus Replication, Liver, 1984: 4; 45-49.
hh	Rasi, et al., Combined Treatment with THymosin Alpha1 and Interferon-Alpha in B and C Virus Chronic Hepatitis, Third International Symposium on Combination Therapies, October 29-312, 1993.
ii	Virgilio, et al., Treatment of Chronic Viral Hepatitis C with Thymosin Alpha1 (TA1) and IFNAlpha: Preliminary Results, Second International Symposium on Combination Therapies, May, 1992.
jj	Garaci, combination Therapy with Thymic Hormone and Interferon in Chronic B Virus Hepatitis; First International Symposium on combination Therapies, March, 1991.
kk	Weiland, O., Interferon Therapy in Chronic Hepatitis C Virus Infection, FEMS Microbiology Reviews 14 (1994) 279-288.
ll	Rubin, et al., Chronic Hepatitis C, Arch Intern Med, Vol. 154, Feb 28, 1994.
mm	The A, B, C, D and E of Viral Hepatitis from the National Institutes of Dental Research, December 22, 1997.
nn	The Virus and its Components, 7/15/98

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Docket Number (Optional)

Army 160

Application Number

09/544,108

Applicant(s)

Sherman

Filing Date

April 6, 2000

Group Art Unit

1648

*EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

MAY 06 2002
MPEP
JC

MAY 06 2002
MPEP
JC

oo	Davis, G. Hepatitis C: Therapy, Information on the Liver in Health and Disease, ALF Professional Education., 1997.
pp	Huang, Followed-up Observation on Antiviral Effect of combined Treatment of Small Dosage of Interferon and Thymosin in Patients With Chronic Hepatitis B, Biosis., 1997, Abstract.
qq	Rudinger, Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence; p. 1-7; Peptide H., (1986)
rr	Hoofnagle, Treatment of Chronic Type C Hepatitis with Alpha Interferon; Seminars in Liver Disease; vol. 9; no. 4(1989)
ss	Hoofnagle, et al.; Randomized, Controlled Trial of Recombinant Human Alpha-Interferon in Patients with Chronic Hepatitis B; Gastroenterology; 1988; 95: 1318-1325.
tt	Perrillo; Treatment of Chronic Hepatitis B with Interferon; Experience in Western Countries; Seminars in Liver Disease; vol. 9; no. 4, 1989
uu	Davis; Editorial , Treatment of Chronic Hepatitis B; vol. 14; vo. 3, 1991
vv	Davis; Interferon in Viral Hepatitis: Role in Pathogenesis and Treatment; Hepatology; vol. 6; vo. 5, -pp 1038-1041, 1986.
ww	Mutchnick, et al.; Thymosin Treatment of Chronic Hepatitis B: A Placebo controlled Pilot Trial; Hepatology; vol. 14, No. 3, 1991.
xx	Kakumu, Effect of Ribavirin and IFNB Therapy for Chronic Hepat. s B ; vol. 94(date ?)
yy	Janssen, Antiviral Combination Therapy of Alpha-Interferon and Zidovudine in Chronic Hepatitis Type B: Results from Randomized Controlled ; 100 (date?)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.